Antiverse collaborates with a top 20 pharma company to identify antibody drug candidates using AI Augmented Drug Discovery platform
Antiverse’s platform accurately identified diverse and rare antibodies
pixabay.com
Using Antiverse’s proprietary AI-Augmented Drug Discovery platform, 248 sequences were identified, of which over 230 were antibody binders. Five of these antibody candidates were found to be cross-reactive.
Antiverse is combining machine learning and phage display techniques to model antibody-antigen interactions. The current version of the platform uses next generation sequencing and AI to provide diverse antibody candidates for any given target. The technology is being developed to enable the development of drugs for “difficult” targets associated with cancer, heart, and lung diseases. The platform will overcome limitations commonly associated with traditional screening including overcoming amplification bias which leads to diversity loss and selection bias which results in the loss of unique antibodies.
Murat Tunaboylu, Chief Executive Officer of Antiverse, said: “We are pleased to collaborate with a top 20 pharma company on this discovery project. Our AI-powered antibody drug discovery platform successfully identified more binders with better diversity to state-of-the-art high-throughput colony picking and bioinformatics pipeline selection. Researchers can find more diverse antibodies by unlocking the full potential of their library/discovery process with our AI-augmented discovery platform and through our fee-for-service offering, we hope to partner with other biotech and pharma companies on projects to identify other challenging targets.”
Other news from the department business & finance
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous